MBNP
MCID: MMB011
MIFTS: 51

Membranous Nephropathy (MBNP)

Categories: Immune diseases, Nephrological diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 57 11 19 28 14
Membranous Glomerulonephritis 11 19 14 16 71 75
Idiopathic Membranous Glomerulonephritis 58 71
Idiopathic Membranous Nephropathy 19 53
Glomerulonephritis, Membranous 19 43
Membranous Nephropathy, Susceptibility to 57
Primary Membranous Glomerulonephritis 58
Extramembranous Glomerulonephritis 19
Primary Membranous Nephropathy 58
Nephropathy Membranous 53
Membranous Gn 19
Mbnp 57
Mgn 19

Characteristics:


Prevelance:

Primary Membranous Glomerulonephritis: 1-9/1000000 (Worldwide, Europe) 58

Classifications:

Orphanet: 58  
Rare renal diseases


External Ids:

Disease Ontology 11 DOID:10976
OMIM® 57 614692
MeSH 43 D015433
NCIt 49 C34645
SNOMED-CT 68 197710000
ICD10 31 N03.2
ICD10 via Orphanet 32 N04.2
UMLS via Orphanet 72 C0086445
Orphanet 58 ORPHA97560
UMLS 71 C0017665 C0086445

Summaries for Membranous Nephropathy

OMIM®: 57 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692) (Updated 08-Dec-2022)

MalaCards based summary: Membranous Nephropathy, also known as membranous glomerulonephritis, is related to nephrotic syndrome and glomerulonephritis. An important gene associated with Membranous Nephropathy is MBNP (?Membranous Nephropathy, Susceptibility To), and among its related pathways/superpathways are Complement cascade and Senescence and autophagy in cancer. The drugs Mycophenolic acid and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, b cells and spleen, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and renal/urinary system

GARD: 19 Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. In many cases, the underlying cause of Membranous nephropathy is not known. Some cases are associated with other conditions (lupus), infections (hepatitis B and C), cancer or as a side effect of certain medications.

Orphanet: 58 A rare glomerular disease, histologically characterized by thickening of the capillary wall, with immune deposits predominantly containing IgG4 and C3 on the sub-epithelial side, and typically manifesting with nephrotic syndrome.

Wikipedia: 75 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Fetomaternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 739)
# Related Disease Score Top Affiliating Genes
1 nephrotic syndrome 31.8 VTN NPHS2 NPHS1 LRP2 HLA-DQA1 CD79A
2 glomerulonephritis 31.4 PLA2R1 NPHS2 NPHS1 MBL2 LRPAP1 LRP2
3 idiopathic nephrotic syndrome 31.4 NPHS2 NPHS1
4 interstitial nephritis 31.4 TINAG PLA2R1 ALB
5 crescentic glomerulonephritis 31.3 PLA2R1 NPHS2 NPHS1 ALB
6 microvascular complications of diabetes 3 31.2 SERPINB7 NPHS1 ALB
7 goodpasture syndrome 31.1 THSD7A PLA2R1 NPHS1 ALB
8 kimura disease 31.1 THSD7A PLA2R1
9 proliferative glomerulonephritis 31.1 PLA2R1 CD79A ALB
10 focal segmental glomerulosclerosis 31.1 VTN NPHS2 NPHS1 MME CD79A CD2AP
11 microvascular complications of diabetes 5 31.0 VTN SERPINE1 ALB
12 iga glomerulonephritis 31.0 SERPINB7 PLA2R1 NPHS2 NPHS1 MBL2 CD79A
13 rapidly progressive glomerulonephritis 31.0 PLA2R1 NPHS1 ALB
14 anti-basement membrane glomerulonephritis 30.9 PLA2R1 ALB
15 primary biliary cholangitis 30.9 MBL2 HLA-DQA1 CD79A ALB
16 chronic kidney disease 30.9 SERPINB7 NPHS2 NPHS1 CD79A ALB
17 lipoid nephrosis 30.8 THSD7A SERPINB7 PLA2R1 NPHS2 NPHS1 CD79A
18 membranoproliferative glomerulonephritis 30.7 VTN THSD7A PLA2R1 NPHS2 NPHS1 MBL2
19 kidney disease 30.6 SERPINE1 SERPINB7 NPHS2 NPHS1 LRP2 CD79A
20 polycystic kidney disease 30.6 NPHS2 NPHS1 LRP2 ALB
21 nephrotic syndrome, type 4 30.5 NPHS2 NPHS1
22 nephrotic syndrome, type 1 30.5 NPHS2 NPHS1 CD2AP
23 dermatitis herpetiformis 30.5 PLAU HLA-DQA1 CD79A
24 urinary tract obstruction 30.5 SERPINE1 NPHS1 ALB
25 guillain-barre syndrome 30.5 HLA-DQA1 CD79A ALB
26 autosomal dominant polycystic kidney disease 30.5 NPHS2 NPHS1 LRP2 ALB
27 mesangial proliferative glomerulonephritis 30.4 PLA2R1 NPHS2 NPHS1 MBL2 CD79A ALB
28 immune-complex glomerulonephritis 30.3 PLA2R1 ALB
29 hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome 30.3 NPHS2 NPHS1
30 cerebral lymphoma 30.3 LRP2 CD79A
31 congenital syphilis 30.3 NPHS2 NPHS1 CD79A
32 nail-patella syndrome 30.2 NPHS2 NPHS1 CD2AP
33 immunoglobulin alpha deficiency 30.2 MBL2 HLA-DQA1 CD79A
34 alport syndrome 30.2 NPHS2 NPHS1 LRP2 CD79A CD2AP ALB
35 wilms tumor 1 30.2 NPHS2 NPHS1 MME CD2AP ALB
36 hemolytic uremic syndrome, atypical 1 30.2 VTN MBL2 ALB
37 chronic pyelonephritis 30.1 MME ALB
38 behcet syndrome 30.1 MBL2 LRP2 HLA-DQA1 ALB
39 congenital membranous nephropathy due to fetomaternal anti-neutral endopeptidase alloimmunization 11.4
40 ficolin 3 deficiency 11.2
41 end stage renal disease 11.0
42 autoimmune disease 10.8
43 glomerular disease 10.8
44 systemic lupus erythematosus 10.8
45 iga nephropathy 1 10.8
46 primary agammaglobulinemia 10.7
47 hepatitis b 10.7
48 lupus erythematosus 10.6
49 graft-versus-host disease 10.5
50 igg4-related disease 10.5

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM®:

614692 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 CD79A MBL2 MME

MGI Mouse Phenotypes related to Membranous Nephropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.28 ALB CD2AP CD79A LRP2 LRPAP1 MBL2

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
10
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
11
Rituximab Approved Phase 4 174722-31-7
12
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
15 Anti-Bacterial Agents Phase 4
16 Anti-Infective Agents Phase 4
17 Calcineurin Inhibitors Phase 4
18 Antitubercular Agents Phase 4
19 Antibiotics, Antitubercular Phase 4
20 Antifungal Agents Phase 4
21 Cyclosporins Phase 4
22 Dermatologic Agents Phase 4
23 Hormones Phase 4
24 Hormone Antagonists Phase 4
25 glucocorticoids Phase 4
26 Anti-Inflammatory Agents Phase 4
27
Methylprednisolone Acetate Phase 4 584547
28 Antineoplastic Agents, Hormonal Phase 4
29 Melanocyte-Stimulating Hormones Phase 4
30 Adrenocorticotropic Hormone Phase 4
31
beta-Endorphin Phase 4
32 Tripterygium Phase 4
33 Antirheumatic Agents Phase 4
34 Antineoplastic Agents, Immunological Phase 4
35 Alkylating Agents Phase 4
36 Antineoplastic Agents, Alkylating Phase 4
37
Angiotensinogen Phase 4 16133225
38 Angiotensin Receptor Antagonists Phase 4
39 Giapreza Phase 4
40 Antihypertensive Agents Phase 4
41 Angiotensin II Type 1 Receptor Blockers Phase 4
42
Deflazacort Approved, Investigational Phase 3 14484-47-0 26709 189821
43
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643
44
Chlorambucil Approved Phase 3 305-03-3 2708
45
Acetaminophen Approved Phase 3 103-90-2 1983
46
Histamine Approved, Investigational Phase 3 51-45-6 774
47
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
48
Obinutuzumab Approved, Investigational Phase 3 949142-50-1
49
Promethazine Approved, Investigational Phase 3 60-87-7 4927
50
Azathioprine Approved Phase 3 446-86-6 2265

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
2 Mycophenolate Mofetil and Tacrolimus vs Tacrolimus Alone for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Completed NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
3 Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy Completed NCT03025828 Phase 4 ACTHar
4 To Compare the Efficacy and Safety of TW vs Valsartan in the MN Completed NCT00518219 Phase 4 TW
5 A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
6 Multitarget Therapy for Idiopathic Membranous Nephropathy Completed NCT04424862 Phase 4 Prednisone, ciclosporin and mycophenolate mofetil;Ponticelli Regimen
7 Clinical Study of Rituximab or Cyclophosphamide Combined With Steroids in the Treatment of Idiopathic Membranous Nephropathy Not yet recruiting NCT05514015 Phase 4 Rituximab;Cyclophosphamide
8 Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
9 A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Unknown status NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
10 A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
11 The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
12 European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) Completed NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
13 Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
14 Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) Completed NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
15 "A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)" Completed NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
16 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
17 Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
18 Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
19 A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Tacrolimus and Corticosteroid as Immunosuppressive Treatment for Lupus Membranous Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
20 A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy Recruiting NCT04629248 Phase 3 Obinutuzumab;Tacrolimus;Methylprednisolone;Acetaminophen;Diphenhydramine
21 Different Immunosuppressive Treatment in Idiopathic Membranous Nephropathy: a Prospective Cohort Recruiting NCT04745728 Phase 3 Prednisone;Cyclophosphamide;Rituximab
22 A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT04743739 Phase 3 Rituximab;cyclosporine
23 Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
24 A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) Unknown status NCT03453619 Phase 2 APL-2
25 A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease Unknown status NCT02682407 Phase 2
26 Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
27 A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN) Completed NCT03285711 Phase 2 Filgotinib;Lanraplenib;Filgotinib placebo;Lanraplenib placebo
28 Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study Completed NCT00694863 Phase 2 tetracosactide hexacetaat
29 A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN) Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
30 BEL116472. A 2 Year Mechanistic Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
31 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
32 An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria Recruiting NCT04456816 Phase 2 100 mg AP1189;Placebo
33 Obinutuzumab for Primary Membranous Nephropathy: a Pilot Study in Patients With Rituximab-resistant or Rituximab-dependent Nephrotic Syndrome and in Patients Intolerant to Rituximab (the ORION Study) Recruiting NCT05050214 Phase 2 Obinutuzumab
34 A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy Recruiting NCT04652570 Phase 1, Phase 2 VB119
35 Personalized Medicine for Membranous Nephropathy Recruiting NCT03804359 Phase 2 Rituximab
36 Rescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target Therapy Recruiting NCT04893096 Phase 2 MOR202
37 An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects With C3G, IgAN, or PMN Recruiting NCT05162066 Phase 2 BCX9930
38 A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN) Recruiting NCT05136456 Phase 2 SHR1459 Low Dose;SHR1459 High Dose;Placebo
39 Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI) Recruiting NCT03949855 Phase 2 Belimumab;Placebo for Belimumab;Rituximab
40 A Multicenter, Randomized, Controlled, Open Phase Ib/ Ⅱ Study Evaluating the Efficacy and Safety of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Primary Membranous Nephropathy. Recruiting NCT05398653 Phase 1, Phase 2 MIL62;Cyclosporine
41 A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy Recruiting NCT04154787 Phase 2 LNP023;Rituximab
42 A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) Active, not recruiting NCT04733040 Phase 2 MOR202
43 A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN) Active, not recruiting NCT04145440 Phase 1, Phase 2 MOR202
44 BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
45 A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN) Completed NCT00805753 Phase 1 ACTH
46 A Prospective Multi-dose Study of Apixaban in Subjects With Nephrotic Syndrome Recruiting NCT04278729 Phase 1 Apixaban 5 MG
47 A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus Terminated NCT00479622 Phase 1 TRU-015
48 Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy: A Randomized, Open, Controlled, Multicenter Clinical Trial Unknown status NCT03864250 Tacrolimus;Prednisone
49 A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation) Unknown status NCT02610595 Jianpixiaozhong particles and Wuse Dietotherapy
50 Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study Unknown status NCT01845688 Losartan Tablets & QingReMoShen Granule;Losartan Tablets & Placebo Granule

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

# Genetic test Affiliating Genes
1 Membranous Nephropathy 28

Anatomical Context for Membranous Nephropathy

Organs/tissues related to Membranous Nephropathy:

MalaCards : Kidney, B Cells, Spleen, Bone Marrow, Neutrophil, Endothelial, Myeloid

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 6048)
# Title Authors PMID Year
1
Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. 62 57
25394321 2014
2
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. 62 57
21323541 2011
3
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. 62 57
21323563 2011
4
Familial membranous nephropathy: an X-linked genetic susceptibility? 62 57
18075275 2008
5
Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. 62 57
12087141 2002
6
Familial membranous nephropathy. 62 57
6439290 1984
7
Association between genetic polymorphisms of the NPHS1 gene and membranous glomerulonephritis in the Taiwanese population. 53 62
20138859 2010
8
Membranous glomerulopathy: the evolving story. 53 62
20110811 2010
9
Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. 53 62
20185638 2010
10
Autoimmune kidney diseases. 53 62
19906361 2010
11
Phosphorylation status of nephrin in human membranous nephropathy. 53 62
19882202 2010
12
[The involvement of neprilysin in the pathogenesis of glomerulopathies]. 53 62
19827739 2009
13
Hepatitis B virus associated focal and segmental glomerular sclerosis: report of two cases and review of literature. 53 62
19169768 2009
14
The transcriptional regulation of podocin (NPHS2) by Lmx1b and a promoter single nucleotide polymorphism. 53 62
19562271 2009
15
Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. 53 62
19820874 2009
16
[Immunosuppressive treatment of idiopathic membranous glomerulonephritis with nephrotic syndrome]. 53 62
20088170 2009
17
B cells and tertiary lymphoid organs in renal inflammation. 53 62
18094677 2008
18
Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. 53 62
18925530 2008
19
Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. 53 62
18272039 2008
20
[Advances in primary glomerular disease in 2007]. 53 62
18847426 2008
21
Expression of nestin in the podocytes of normal and diseased human kidneys. 53 62
17255215 2007
22
Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. 53 62
17200187 2007
23
Role of podocyte slit diaphragm as a filtration barrier. 53 62
16889564 2006
24
Glomerular clusterin is associated with PKC-alpha/beta regulation and good outcome of membranous glomerulonephritis in humans. 53 62
16775601 2006
25
Familial aggregation of primary glomerulonephritis in an Italian population isolate: Valtrompia study. 53 62
16528253 2006
26
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. 53 62
16285662 2005
27
Mechanisms of immune-deposit formation and the mediation of immune renal injury. 53 62
16189625 2005
28
Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. 53 62
15882266 2005
29
IgA deficiency and membranous glomerulonephritis presenting as nephrotic syndrome. 53 62
15711951 2005
30
Mouse model of membranous nephropathy induced by cationic bovine serum albumin: antigen dose-response relations and strain differences. 53 62
15385633 2004
31
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. 53 62
15464186 2004
32
Glomerular expression of biglycan and decorin and urinary levels of decorin in primary glomerular disease. 53 62
14964452 2004
33
Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. 53 62
14633129 2003
34
[Pathogenesis of immune glomerulonephritis]. 53 62
15008213 2003
35
Pathological demography of native patients in a nephrology center in China. 53 62
14527370 2003
36
Detection of nuclear factor-kappaB in IgA nephropathy using Southwestern histochemistry. 53 62
12830459 2003
37
Urinary excretion of complement C3d in patients with renal diseases. 53 62
12795640 2003
38
Glomerular expression of connective tissue growth factor mRNA in various renal diseases. 53 62
15012739 2003
39
IgA deficiency with membranous glomerulonephritis: a case report and review. 53 62
12649548 2003
40
Depletion of clusterin in renal diseases causing nephrotic syndrome. 53 62
12427144 2002
41
Differential expression of nephrin in acquired human proteinuric diseases. 53 62
12407641 2002
42
Frequency of renal pathology in Spain 1994-1999. 53 62
12198210 2002
43
Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. 53 62
11912254 2002
44
Specific tissue distribution of megsin, a novel serpin, in the glomerulus and its up-regulation in IgA nephropathy. 53 62
11527413 2001
45
Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. 53 62
11337370 2001
46
Expression of nephrin in pediatric kidney diseases. 53 62
11158218 2001
47
No complement receptor 1 stumps on podocytes in human glomerulopathies. 53 62
11135068 2001
48
Clusterin is up-regulated in glomerular mesangial cells in complement-mediated injury. 53 62
11135066 2001
49
Vascular hyperpermeability in nephrotic edema. 53 62
10867533 2000
50
Changing incidence of glomerular diseases in adults. 53 62
10793022 2000

Variations for Membranous Nephropathy

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex involved in cell-matrix adhesion GO:0098637 9.62 VTN PLAU
2 slit diaphragm GO:0036057 9.56 NPHS2 NPHS1
3 serine protease inhibitor complex GO:0097180 9.46 SERPINE1 PLAU
4 peptidase inhibitor complex GO:1904090 9.26 VTN SERPINE1
5 rough endoplasmic reticulum lumen GO:0048237 8.92 VTN LRPAP1

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of plasminogen activation GO:0010757 9.56 SERPINE1 PLAU
2 regulation of receptor-mediated endocytosis GO:0048259 9.46 LRPAP1 CD2AP
3 replicative senescence GO:0090399 9.43 SERPINE1 PLA2R1 MME
4 negative regulation of fibrinolysis GO:0051918 9.1 VTN SERPINE1 PLAU

Sources for Membranous Nephropathy

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....